Luye Pharma Group (2186) AI Stock Analysis

• Market Cap: $14.42B
• Dividend Yield: N/A
• Average Volume (3M): 94.41M
• Price to Earnings (P/E): 28.5
• Beta (1Y): 0.96
• Revenue Growth: -3.12%
• EPS Growth: -12.71%
• Country: HK
• Employees: 5,150
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.02
• Shares Outstanding: 3,782,838,400
• 10 Day Avg. Volume: 105,743,756
• 30 Day Avg. Volume: 94,412,891
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 2.09
• Enterprise Value/Gross Profit: 3.13
• Enterprise Value/Ebitda: 7.07
• 1Y Price Target: $4.16
• Price Target Upside: 8.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 71 Outperform
• Price Target: HK$5.00 ▲(30.21% Upside)

Luye Pharma Group scores well due to strong technical momentum and solid financial performance. However, valuation concerns and inconsistent cash flow growth slightly dampen the overall score.

Luye Pharma Group Business Overview & Revenue Model

Company Description

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

How the Company Makes Money

Luye Pharma Group generates revenue primarily through the sale of its pharmaceutical products across a wide range of therapeutic areas. The company's key revenue streams include the sale of proprietary drugs and the licensing of its products for distribution in different markets. Luye Pharma also invests in research and development to create new drugs, which can lead to additional revenue through patents and partnerships with other pharmaceutical companies. Strategic collaborations and partnerships with other healthcare organizations and research institutions further contribute to the company's earnings, enabling it to expand its market presence and enhance its product offerings.

Luye Pharma Group Financial Statement Overview

Summary

Luye Pharma Group demonstrates strong profitability with healthy EBIT and EBITDA margins. The balance sheet is solid with a moderate debt-to-equity ratio, but cash flow stability is a concern due to inconsistent free cash flow growth. Overall, the financial structure is robust, though sustaining growth momentum is challenging.

Income Statement

Luye Pharma Group shows robust gross and net profit margins, indicating efficient cost management and profitability. However, the revenue growth has been inconsistent, showing a decline in the most recent year. EBIT and EBITDA margins are healthy, reflecting strong operational performance.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging. ROE is relatively stable, indicating effective utilization of equity. The equity ratio signifies a solid capital structure, though there is room for improvement in reducing debt levels.

Cash Flow

Cash flow stability is a concern, with inconsistent free cash flow growth and operating cash flow to net income ratios. However, the company has managed to maintain positive cash flow from operations in recent years, indicating operational efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.06B	6.14B	5.98B	5.20B	5.54B
Gross Profit	4.04B	4.20B	4.14B	3.40B	3.99B
EBITDA	1.79B	2.08B	1.81B	906.88M	1.88B
Net Income	471.89M	532.61M	604.81M	-144.78M	706.59M
Balance Sheet
Total Assets	29.61B	25.49B	24.25B	22.58B	20.63B
Cash, Cash Equivalents and Short-Term Investments	6.50B	6.11B	5.54B	5.51B	5.41B
Total Debt	10.32B	8.42B	9.10B	9.49B	9.98B
Total Liabilities	13.86B	11.96B	13.21B	13.47B	12.53B
Stockholders Equity	14.15B	12.53B	10.18B	8.49B	7.89B
Cash Flow
Free Cash Flow	0.00	430.23M	490.14M	-1.36B	-486.43M
Operating Cash Flow	0.00	1.60B	1.65B	182.37M	1.03B
Investing Cash Flow	0.00	-1.42B	-1.66B	-3.44B	138.20M
Financing Cash Flow	0.00	841.60M	54.15M	1.88B	253.98M

Luye Pharma Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2186, the sentiment is Positive. The current price of 3.84 is below the 20-day moving average (MA) of 3.94, above the 50-day MA of 3.60, and above the 200-day MA of 2.63, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 19.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2186.

Luye Pharma Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2186	71 Outperform	$14.42B	28.53	3.53%	―	-3.12%	-12.71%
Sector *	51 Neutral	$7.35B	-0.20	-44.86%	2.33%	28.96%	-1.05%
CHJTF	―	$15.18B	24.90	13.20%	2.81%	―	―
SHPHF	―	$1.64B	―	-4.93%	2.69%	―	―
C1P	―	€1.23B	9.41	23.28%	―	―	―
6826	76 Outperform	HK$12.59B	15.07	7.25%	3.75%	-1.81%	-3.79%
1558	65 Neutral	$12.65B	24.20	5.88%	10.31%	-42.02%	-76.29%

Luye Pharma Group Corporate Events

Luye Pharma Converts Tranche A Bonds to Shares

Luye Pharma Group Ltd. announced the conversion of a portion of its Tranche A Bonds, valued at US$10,000,000, at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial management and compliance with regulatory requirements, aiming to maintain transparency and equal information dissemination among investors.

The most recent analyst rating on (HK:2186) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.

Luye Pharma Group Announces Successful AGM Results

Luye Pharma Group Ltd. held its Annual General Meeting on May 28, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of board members, the re-appointment of Ernst & Young as auditors, and granting mandates for share issuance and repurchase. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.

The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.13 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.